Abstract
Objective: To explore the possible mechanism for treating NRR in arrhythmia using network pharmacology and molecular docking in this study.
Methods: Active compounds and targets for NRR were retrieved from the Traditional Chinese Medicine Systems Pharmacology (TCMSP) Database and Analysis Platform, SymMap, and the Encyclopedia of Traditional Chinese Medicine (ETCM) databases. Arrhythmia-related genes were acquired from the Comparative Toxicogenomics Database (CTD) and the GeneCards database. Overlapping targets of NRR associated with arrhythmia were acquired and displayed via a Venn diagram. DAVID was applied for GO and KEGG pathway analyses. Cytoscape software and its plug-in were used for PPI network construction, module division and hub nodes screening. Auto- Dock Vina and qRT-PCR were carried out for validation.
Results: In total, 21 active compounds and 57 targets were obtained. Of these, coumarin was the predominant category which contained 15 components and 31 targets. There were 5 key targets for NRR in treating arrhythmia. These targets are involved in the apoptotic process, extrinsic apoptotic signaling pathway in the absence of ligand, and endopeptidase activity involved in the apoptotic process by cytochrome c. The main pathways were the p53 signaling pathway, Hepatitis B and apoptosis. The molecular docking and qRT-PCR displayed good effects on hub node regulation in NRR treatment.
Conclusion: NRR plays an important role in anti-apoptotic mechanisms that modulate the p53 signaling pathway, which may provide insight for future research and clinical applications focusing on arrhythmia therapy.
Graphical Abstract
[http://dx.doi.org/10.4022/jafib.2404] [PMID: 33024504]
[http://dx.doi.org/10.1016/j.tcm.2018.09.014] [PMID: 30268648]
[http://dx.doi.org/10.1016/j.ccl.2017.08.007] [PMID: 29173673]
[http://dx.doi.org/10.3389/fphar.2019.00123] [PMID: 30846939]
[http://dx.doi.org/10.1155/2020/5217405] [PMID: 33299870]
[http://dx.doi.org/10.3390/ijms21062071] [PMID: 32197305]
[http://dx.doi.org/10.1016/j.drudis.2014.01.001] [PMID: 24811798]
[http://dx.doi.org/10.3969/j.issn.1001-1528.2019.10.033]
[http://dx.doi.org/10.11954/ytctyy.201905061]
[http://dx.doi.org/10.7501/j.issn.0253-2670.2021.19.034]
[http://dx.doi.org/10.1002/anie.202006725] [PMID: 32780485]
[http://dx.doi.org/10.1038/s41467-021-27853-w] [PMID: 35017485]
[http://dx.doi.org/10.3390/ijms20112783] [PMID: 31174387]
[http://dx.doi.org/10.1016/j.cell.2016.12.029] [PMID: 28111073]
[http://dx.doi.org/10.1111/cpr.12190] [PMID: 26009974]
[http://dx.doi.org/10.1007/978-1-4939-6634-9_5] [PMID: 27873247]
[http://dx.doi.org/10.1007/s11427-018-9342-2] [PMID: 30054833]
[http://dx.doi.org/10.1016/j.pharmthera.2021.107843] [PMID: 33811957]
[http://dx.doi.org/10.2174/138620712798280826] [PMID: 21846324]
[http://dx.doi.org/10.1186/1758-2946-6-13] [PMID: 24735618]
[http://dx.doi.org/10.1093/nar/gky1021] [PMID: 30380087]
[http://dx.doi.org/10.1093/nar/gky987] [PMID: 30365030]
[http://dx.doi.org/10.1093/nar/gky868] [PMID: 30247620]
[http://dx.doi.org/10.1002/cpbi.5]
[http://dx.doi.org/10.1101/gr.1239303] [PMID: 14597658]
[http://dx.doi.org/10.1038/nprot.2008.211] [PMID: 19131956]
[http://dx.doi.org/10.1093/nar/gkn923] [PMID: 19033363]
[http://dx.doi.org/10.1016/j.jchromb.2018.06.006] [PMID: 29913336]
[http://dx.doi.org/10.13989/j.cnki.0517-6611.2010.24.095]
[http://dx.doi.org/10.52547/rbmb.10.2.183] [PMID: 34604408]
[http://dx.doi.org/10.1016/j.ijcard.2015.01.048] [PMID: 25662045]
[http://dx.doi.org/10.1016/j.hjc.2018.02.009] [PMID: 29501704]
[http://dx.doi.org/10.12659/MSM.895715] [PMID: 27141955]
[http://dx.doi.org/10.3892/etm.2013.899] [PMID: 23403858]
[http://dx.doi.org/10.1016/j.toxlet.2019.09.024] [PMID: 31585160]
[http://dx.doi.org/10.1002/cbf.3578] [PMID: 32767595]
[http://dx.doi.org/10.1080/10799893.2020.1772297] [PMID: 32460597]
[http://dx.doi.org/10.1111/j.1540-8167.2011.02186.x] [PMID: 21954843]
[http://dx.doi.org/10.1097/CCM.0b013e31818a89f4] [PMID: 20449908]
[http://dx.doi.org/10.21203/rs.3.rs-1047765/v1]